68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer.
68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer.
复制标题
68Ga-NOTA-PRGD2 PET/CT 用于肺癌患者的整合素成像。
DOI：
10.2967/jnumed.115.160648
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Chen X
中科院分区：
文献类型：
--
作者：
Zheng K;Liang N;Zhang J;Lang L;Zhang W;Li S;Zhao J;Niu G;Li F;Zhu Z;Chen X
本研究旨在评估 68Ga-NOTA-PRGD2（NOTA-PRGD2 是 NOTA-PEG4-E[c(RGDfK)]2）PET/CT 对肺癌的诊断价值。 91 名 CT 上疑似肺部病变的患者（48 名男性和 43 名女性；年龄 22-82 岁）在知情同意下入组。静脉注射 117.7 ± 37.7 MBq 68Ga-NOTA-PRGD2 后，15 名患者立即接受动态全身 PET/CT 扫描 1-2 小时，其余 76 名患者在推注后 30 ± 10 分钟接受全身 PET/CT 扫描。每名患者还接受了标准 18F-FDG PET/CT 进行比较。注射68Ga-NOTA-PRGD2后未发现副作用。 68Ga-NOTA-PRGD2 迅速从血池中清除，并主要通过泌尿系统排出体外。已证实的恶性肿瘤的标准化摄取值显着高于良性肿瘤。平均标准化摄取值大于1.3被认为是恶性，68Ga-NOTA-PRGD2 PET/CT诊断肺癌的敏感性、特异性和准确性分别为83.8%（57/68）、91.3%（21/23）和85.7%（78/91）。 68Ga-NOTA-PRGD2对肺癌的诊断价值与18F-FDG PET/CT相当。然而，68Ga-NOTA-PRGD2 PET/CT在评估淋巴结转移方面比18F-FDG PET/CT更具特异性，阳性和阴性预测值分别为90.0%（27/30）和93.8%（121/129），而18F-FDG PET/CT的阳性和阴性预测值分别为30.2%（29/96）和90.5%。 (57/63)。本研究表明 68Ga-NOTA-PRGD2 PET/CT 在肺癌诊断中的功效。 68Ga-NOTA-PRGD2 PET/CT在判断转移淋巴结方面较18F-FDG PET/CT具有显着优势，特异性更高。
This study was designed to assess the diagnostic value of 68Ga-NOTA-PRGD2 (NOTA-PRGD2 is NOTA-PEG4-E[c(RGDfK)]2) PET/CT in lung cancer. Ninety-one patients (48 men and 43 women; age, 22–82 y) with suspected lung lesions on CT were enrolled with informed consent. Immediately after intravenous injection of 117.7 ± 37.7 MBq of 68Ga-NOTA-PRGD2, 15 patients underwent dynamic whole-body PET/CT scans for 1–2 h, and the remaining 76 patients underwent whole-body PET/CT scans at 30 ± 10 min after bolus injection. Each patient also underwent standard 18F-FDG PET/CT for comparison. No side effect was found after 68Ga-NOTA-PRGD2 injection. 68Ga-NOTA-PRGD2 was rapidly cleared from the blood pool and primarily excreted through the urinary system. The standardized uptake values of proven malignancies were significantly higher than those of the benign ones. With an average standardized uptake value of greater than 1.3 being considered malignant, the sensitivity, specificity, and accuracy of 68Ga-NOTA-PRGD2 PET/CT in diagnosing lung cancer were 83.8% (57/68), 91.3% (21/23), and 85.7% (78/91), respectively. The diagnostic value of 68Ga-NOTA-PRGD2 for lung cancer is comparable to that of 18F-FDG PET/CT. However, 68Ga-NOTA-PRGD2 PET/CT is more specific than 18F-FDG PET/CT in assessing lymph node metastasis, with positive and negative predictive values of 90.0% (27/30) and 93.8% (121/129), respectively, whereas those of 18F-FDG PET/CT were 30.2% (29/96) and 90.5% (57/63), respectively. This study indicates the efficacy of 68Ga-NOTA-PRGD2 PET/CT in lung cancer diagnosis. 68Ga-NOTA-PRGD2 PET/CT shows significant advantage over 18F-FDG PET/CT in judging metastatic lymph nodes with higher specificity.